![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Artemis Therapeutics Inc (PK) | USOTC:ATMS | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.498 | 0.181 | 0.50 | 0.00 | 01:00:00 |
☑ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
DELAWARE
|
84-1417774
|
(State or other jurisdiction of
|
(I.R.S. Employer Identification No.)
|
incorporation or organization)
|
|
18 East 16th Street, Suite 307, New York, NY
|
10003
|
(Address of principal executive offices)
|
(Zip Code)
|
Large accelerated filer
☐
|
Accelerated filer
☐
|
Non-accelerated filer
☐
(do not check if a smaller reporting company)
|
Smaller reporting company
☒
|
Emerging growth company
☐
|
|
|
|
PAGE
|
|
|
|
4 | ||
|
|
|
4 | ||
|
|
|
|
5 | |
|
|
|
|
6 | |
|
|
|
|
7 | |
|
|
|
|
8 | |
|
|
|
|
9 | |
|
|
|
19 | ||
|
|
|
22 | ||
|
|
|
23 | ||
|
|
|
|
23 | |
23 | ||
|
|
|
24 |
PAGE
|
|
5
|
|
6
|
|
7
|
|
8
|
|
9-18
|
As of
June 30,
|
As of
December 31,
|
||||||||
Note
|
2018
(Unaudited)
|
2017
(Audited)
|
|||||||
ASSETS
|
|||||||||
Current assets
|
|||||||||
Cash and cash equivalents
|
148
|
525
|
|||||||
Other accounts receivable and prepaid expenses
|
33
|
58
|
|||||||
Total current assets
|
181
|
583
|
|||||||
TOTAL ASSETS
|
181
|
583
|
|||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|||||||||
Current liabilities
|
|||||||||
Accrued expenses and other payables
|
53
|
53
|
|||||||
Total current liabilities
|
53
|
53
|
|||||||
Long Term liabilities
|
|||||||||
Derivative warrant liabilities
|
7B
|
265
|
428
|
||||||
Commitments and Contingencies
|
3
|
-
|
-
|
||||||
Total long term liabilities
|
265
|
428
|
|||||||
Total Liabilities
|
318
|
481
|
|||||||
Stockholders' equity
|
|||||||||
Series A convertible preferred stock, $0.01 par value - authorized: 10,000,000 shares; issued and outstanding: 453 shares as of June 30, 2018 and December 31, 2017
|
(*
|
)
|
(*
|
)
|
|||||
Series C convertible preferred stock, $0.01 par value - authorized: 250 shares; issued and outstanding: 250 shares as of June 30, 2018 and December 31, 2017
|
(*
|
)
|
(*
|
)
|
|||||
Common stock, $0.01 par value - authorized: 51,000,000; issued and outstanding: 5,153,380 as of June 30, 2018 and December 31, 2017
|
52
|
52
|
|||||||
Additional paid in capital
|
7
|
1,570
|
1,457
|
||||||
Accumulated deficit
|
(1,759
|
)
|
(1,407
|
)
|
|||||
Total stockholders' equity
|
(137
|
)
|
102
|
||||||
TOTAL
LIABILITIES AND
STOCKHOLDERS’ EQUITY
|
181
|
583
|
Six Months
Ended June
30, 2018
|
Six Months
Ended June
30, 2017
|
Three Months
Ended June
30, 2018
|
Three Months
Ended June
30, 2017
|
|||||||||||||
Research and development expenses
|
129
|
146
|
58
|
99
|
||||||||||||
General and administrative
|
383
|
280
|
154
|
142
|
||||||||||||
Operating loss
|
512
|
426
|
212
|
241
|
||||||||||||
Finance Income (Expense)
|
160
|
5
|
71
|
(5
|
)
|
|||||||||||
Net loss
|
352
|
421
|
141
|
246
|
||||||||||||
Net loss per share, basic and diluted
(Note 6)
|
0.06
|
0.08
|
0.02
|
0.04
|
||||||||||||
Weighted average number of common stock used in calculation of net loss per share:
|
||||||||||||||||
Basic and diluted
|
5,153,380
|
4,818,952
|
5,153,380
|
4,819,725
|
Common Stock
|
Preferred Stock A
|
Preferred Stock C
|
Additional
paid-in Capital
|
Total
|
||||||||||||||||||||||||||||||||
Number of
Shares
|
USD
|
Number
|
Amount
|
Number
|
Amount
|
Accumulated
(deficiency)
|
stockholders'
Equity
|
|||||||||||||||||||||||||||||
Balance as of December 31, 2017
|
5,153,380
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,457
|
(1,407
|
)
|
102
|
||||||||||||||||||||||||
Share based compensation
|
113
|
113
|
||||||||||||||||||||||||||||||||||
Net loss
|
(352
|
)
|
(352
|
)
|
||||||||||||||||||||||||||||||||
Balance as of June 30, 2018
|
5,153,380
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,570
|
(1,759
|
)
|
(137
|
)
|
Six Months
Ended June 30,
2018
|
Six Months
Ended June 30,
2017
|
Three Months
Ended June 30,
2018
|
Three Months
Ended June 30,
2017
|
|||||||||||||
Net cash used in operating activities
|
||||||||||||||||
Net Loss
|
(352
|
)
|
(421
|
)
|
(141
|
)
|
(236
|
)
|
||||||||
Share based compensation expenses
|
113
|
47
|
12
|
32
|
||||||||||||
Decrease in other accounts receivable and prepaid expenses
|
25
|
25
|
11
|
6
|
||||||||||||
Decrease (increase) in accrued expenses and other payables
|
-
|
(3
|
)
|
1
|
(6
|
)
|
||||||||||
Change in the fair value of derivative warrant liability
|
(163
|
)
|
-
|
(74
|
)
|
-
|
||||||||||
Net cash used in operating activities
|
(377
|
)
|
(352
|
)
|
(191
|
)
|
(204
|
)
|
||||||||
(Decrease) in cash and cash equivalents
|
(377
|
)
|
(352
|
)
|
(191
|
)
|
(204
|
)
|
||||||||
Cash and cash equivalents at the beginning of the period
|
525
|
907
|
339
|
759
|
||||||||||||
Cash and cash equivalents at the end of the period
|
148
|
555
|
148
|
555
|
A. |
New York Global Innovations Inc. (the "Predecessor Company") was originally incorporated under the laws of the State of Nevada, on April 22, 1997. On July 8, 2003, the Predecessor Company effected a reincorporation from Nevada to Delaware through a merger with and into its wholly-owned subsidiary, Inksure Technologies (Delaware) Inc., which was incorporated on September 30, 2003. The surviving corporation in the merger was Inksure Technologies (Delaware) Inc., which thereupon renamed itself Inksure Technologies Inc. In 2014, following the sale of its assets to Spectra Systems Corporation, the Predecessor Company changed its name to New York Global Innovations Inc.
|
B. |
Establishment of Artemis (the "accounting acquirer"):
|
A. |
Unaudited Interim Financial Statements
|
B. |
Significant Accounting Policies
|
C. |
Recent
Accounting Standards:
|
A. |
Tax rates applicable to the income
|
A. |
Tax rates applicable to the income
(cont.)
|
B. |
Deferred income taxes
|
As of
June 30,
2018
|
As of
December 31,
2017
|
|||||||
Deferred tax assets:
|
||||||||
Deferred taxes due to carryforward losses
|
2,840
|
2,763
|
||||||
Valuation allowance
|
(2,840
|
)
|
(2,763
|
)
|
||||
Net deferred tax asset
|
-
|
-
|
C. |
Tax loss carry-forwards
|
As of
June 30,
2018
|
As of
December 31,
2017
|
|||||||
Israel
|
4,753
|
4,684
|
||||||
United States (*)
|
8,320
|
7,988
|
||||||
13,073
|
12,672
|
ISSUANCE DATE
|
NUMBER OF WARRANTS OUTSTANDING as June 30, 2018
|
EXERCISE PRICE
|
EXERCISABLE THROUGH
|
||||||
|
|
||||||||
October 2017 *
|
275,000
|
$
|
2.00
|
October 2022
|
|
Six Months
Ended
June 30, 2018
|
Six Months
Ended
June 30, 2017
|
Three Months
Ended
June 30, 2018
|
Three Months
Ended
June 30, 2017
|
||||||||||||
Net loss available to stockholders of the company
|
(352
|
)
|
(421
|
)
|
(141
|
)
|
(246
|
)
|
||||||||
Net loss attributable to stockholders of preferred shares
|
53
|
50
|
21
|
30
|
||||||||||||
|
||||||||||||||||
Net loss used in the calculation of basic loss per share
|
300
|
371
|
120
|
217
|
||||||||||||
|
||||||||||||||||
Net loss per share
|
0.06
|
0.08
|
0.02
|
0.04
|
||||||||||||
|
||||||||||||||||
Weighted average number of common stock used in the calculation of net loss per share
|
5,153,380
|
4,818,952
|
5,153,380
|
4,819,725
|
A. |
Stockholders Rights:
|
B. |
Issuance of Shares:
|
B. |
Issuance of Shares (Cont.):
|
C. |
Reverse Stock Split:
|
D. |
Options issued to employees and consultants:
|
D. |
Options issued to employees and consultants (Cont.):
|
For the six months ended
June 30, 2018
|
||||||||||||
Number of
stock options
|
Weighted average exercise price
|
Aggregate
intrinsic value
|
||||||||||
Outstanding at beginning of period
|
334,168
|
0.95
|
||||||||||
Granted
|
98,528
|
1.30
|
||||||||||
Exercised
|
-
|
-
|
||||||||||
Cancelled
|
-
|
-
|
||||||||||
Outstanding at end of period
|
432,696
|
1.03
|
6,529
|
|||||||||
Options exercisable at period end
|
153,570
|
0.89
|
23,665
|
D. |
Options issued to employees and consultants (Cont.):
|
Exercise price
|
Stock options
outstanding as of
June 30,
|
Weighted average
remaining contractual
life – years as of
June 30,
|
Stock options
exercisable as of
June 30,
|
|||||||||||
$
|
2 0 1 8
|
2018
|
2018
|
|||||||||||
0.01
|
91,528
|
8.15
|
49,284
|
|||||||||||
1.30
|
242,640
|
9.20
|
50,550
|
|||||||||||
1.30
|
98,528
|
9.72
|
53,736
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
CONTROLS AND PROCEDURES
|
OTHER INFORMATION
|
OTHER INFORMATION
|
EXHIBITS
|
EXHIBIT
NUMBER
|
|
DESCRIPTION
|
|
|
|
|
|
|
|
|
|
|
|
|
101.1
|
|
The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 formatted in XBRL (eXtensible Business Reporting Language): (i) the Interim Condensed Consolidated Balance Sheets, (ii) the Interim Condensed Consolidated Statements of Comprehensive Loss, (iii) the Interim Condensed Statements of Shareholders Equity, (iv) the Interim Condensed Consolidated Statements of Cash Flows and (v) related notes to these financial statements, tagged as blocks of text and in detail.*
|
|
ARTEMIS THERAPEUTICS, INC.
|
|
|
|
|
Dated: August 14, 2018
|
By:
|
/s/ Brian Culley
|
|
|
Brian Culley
|
|
|
Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
Dated: August 14, 2018
|
By:
|
/s/ Chanan Morris
|
|
|
Chanan Morris
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial and Accounting Officer)
|
1 Year Artemis Therapeutics (PK) Chart |
1 Month Artemis Therapeutics (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions